BTX-A51
A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 80 patients (estimated)
- Sponsors
- Edgewood Oncology, Inc.
- Tags
- CK1-Alpha Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1527
- NCT Identifier
- NCT04243785
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.